Coronavirus (COVID-19) News
Found 2,541 articles
Superior Neutralizing Antibody Titer Levels Against Omicron BF.7 And BA.2.75 Of The Company's Two-Component Recombinant COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
Jiangsu Recbio Technology Co., Ltd. is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant two-component COVID-19 vaccine ReCOV in the Philippines.
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
Revive Therapeutics Ltd. announced that it has submitted the Type C meeting request package to the U.S. Food & Drug Administration to obtain agreement on the revised protocol endpoints for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
Ocugen gets the go-ahead from the FDA to trial its late-stage regenerative cell therapy.
More exercise linked to less-severe COVID-19 outcomes
Kaiser Permanente members who were more physically active prior to being diagnosed with COVID-19 had a lower risk of severe outcomes, according to research published Dec. 15, 2022, in the American Journal of Preventive Medicine.
Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
Jiangsu Recbio Technology Co., Ltd. is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent COVID-19 vaccine ReCOV in the Philippines.
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA
Ascletis Pharma Inc. announces that China National Medical Products Administration has approved the Investigational New Drug application for ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease for COVID-19.
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announced new preclinical data showing KIN001’s strong antiviral efficacy against the SARS-CoV-2 Omicron subvariants BA.2 and BA.5.
Eurofins Launches BQ.1 and BQ.1.1 Droplet Digital PCR Assay (ddPCR) for SARS-CoV-2 Wastewater Testing
Eurofins Environment Testing Northern California: Wastewater and Eurofins Pandemic Prevention Services launched a droplet digital PCR assay for the combined quantitative analysis of SARS-CoV-2 Variants of Concern BQ.1 and BQ.1.1 in wastewater.
Pictor announces funding round after successful launch in New Zealand and USA of SARS-CoV-2 Antibody Test
$5 million raise to accelerate global market development & product development
CORRECTION: Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant
Halberd Corporation's Covid research has led to a scientific article titled, "A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant." The article has been peer reviewed and accepted for publication, but has not yet been published.
Therma Bright Invests in the Development of Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD)
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies
New Health+™ Long COVID Report Translates Lived Experiences into Evidence-Based Recommendations
The US Department of Health and Human Services and its Office of the Assistant Secretary of Health recently released a Health+ Long COVID Human-Centered Design Report produced by Coforma's Health+™ program.
Dompé: New Published Data Point to Spike Protein Interactions with Estrogen Receptors as a cause for Coagulopathy in COVID-19 Patients, Signaling Sex Effects and a Path to Improved Vaccines
Dompé farmaceutici announced new data revealing a novel function of the SARS-CoV-2 Spike protein interaction with the human Estrogen Receptor Alpha that may lead to the severe coagulopathy observed in patients with COVID-19 and a minority of subjects receiving the SARS-CoV-2 vaccine.
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
Clover Biopharmaceuticals, Ltd. and the International Vaccine Institute announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.
World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults
Novavax, Inc. announced that the World Health Organization has issued an updated Emergency Use Listing for Nuvaxovid™ COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 as a primary series of two doses in adolescents aged 12 through 17 and as a booster in adults aged 18 and older.
In a volatile year, marked with challenges, BioSpace is taking a pause to reflect on the many “wins” in biopharma.
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
Revive Therapeutics Ltd. announced that it will submit the Type C meeting request package to the US FDA by mid-December 2022, which will outline the overall development plan and Pre-Dose selection data supporting the latest revised endpoints for the Company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.
Sense and R-Biopharm Nederland B.V. Agree to Distribute Rapid, Instrument-Free Molecular COVID-19 Test in the Netherlands, Belgium, and Luxembourg
Global molecular diagnostics innovator Sense Biodetection announced it has entered into a strategic agreement with R-Biopharm Nederland B.V. for the non-exclusive distribution in the Netherlands, Belgium, and Luxembourg of Sense’s Veros instrument-free, point-of-care molecular testing platform.
Pfizer and BioNTech reported positive data Friday from their Omicron BA.4/BA.5-adapted bivalent booster. This followed a similar announcement by Moderna Monday.
Therma Bright Inc. to Acquire an Exclusive License for a Patented Digital Cough Based Technology to Detect Respiratory Diseases
Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has entered into a letter of intent ("LOI") with AI4LYF LLC ("AI4LYF") for the exclusive licensing rights for a digital cough-based diagnosis screening technology.